Algenpantucel-L immunotherapy in pancreatic adenocarcinoma

Papers of special note have been highlighted as: •• of considerable interest

References

• 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65(1), 5–29 (2015).
  MedlineGoogle Scholar
• 2 Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364(19), 1817–1825 (2011).
  Medline CASGoogle Scholar
• 3 Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369(18), 1691–1703 (2013).
  Medline CASGoogle Scholar
• 4 Loehrer PJ Sr, Feng Y, Cardenes H et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 29(31), 4105–4112 (2011).
  Medline CASGoogle Scholar
• 5 Hammel P, Huguet F, Van Laethem J-L et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international Phase III LAP 07 study. 2013 ASCO Annual Meeting. IL, USA, 31 May–4 June 2013 (Abstract 31, Suppl. 18, LBA4003).
  Google Scholar
• 6 Oettle H, Neuhaus P, Hochhaus A et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310(14), 1473–1481 (2013).
  Medline CASGoogle Scholar
• 7 Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15(6), 2403–2413 (1997).
  Medline CASGoogle Scholar
• 8 Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801–1806 (2008).
  Medline CASGoogle Scholar
• 9 Nones K, Waddell N, Song S et al. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT–ROBO, ITGA2 and MET signaling. Int. J. Cancer 135(5), 1110–1118 (2014).
  Medline CASGoogle Scholar
• 10 Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin. Cancer Res. 18(16), 4266–4276 (2012).
  Medline CASGoogle Scholar
• 11 Fukunaga A, Miyamoto M, Cho Y et al. CD8⁺ tumor-infiltrating lymphocytes together with CD4⁺ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28(1), e26–e31 (2004).
  MedlineGoogle Scholar
• 12 Dodson LF, Hawkins WG, Goedegebuure P. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy 3(4), 517–537 (2011).
  CASGoogle Scholar
• 13 Esposito I, Menicagli M, Funel N et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J. Clin. Pathol. 57(6), 630–636 (2004).
  Medline CASGoogle Scholar
• 14 Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3⁺ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 12(18), 5423–5434 (2006).
  Medline CASGoogle Scholar
• 15 Sideras K, Braat H, Kwekkeboom J et al. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat. Rev. 40(4), 513–522 (2014).
  Medline CASGoogle Scholar
• 16 Le DT, Wang-Gillam A, Picozzi V et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. 33(12), 1325–1333 (2015).
  Medline CASGoogle Scholar
• 17 Dagleish MP, Pemberton AD, Mcaleese SM, Thornton EM, Miller HR, Scudamore CL. Improved hepatic and pancreatic localisation of the equine alpha-1-proteinase inhibitor family of serpins using an antigen enhancement technique and a monoclonal antibody. Res. Vet. Sci. 65(3), 215–221 (1998).
  Medline CASGoogle Scholar
• 18 Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024), 1612–1616 (2011).
  Medline CASGoogle Scholar
• 19 Wang-Gillam A, Nywening TM, Sanford DE et al. Phase IB study of FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma (PC). Presented at: 2015 Gastrointestinal Cancers Sympsium. CA, USA, 15–17 January 2015 (Abstract 338, Suppl. 3).
  Google Scholar
• 20 Lutz E, Yeo CJ, Lillemoe KD et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann. Surg. 253(2), 328–335 (2011).
  MedlineGoogle Scholar
• 21 Laheru D, Lutz E, Burke J et al. Allogeneic GM-CSF secreting tumor immunotherapy (GVAX^®) alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility and immune activation. Clin. Cancer Res. 14(5), 1455–1463 (2008).
  Medline CASGoogle Scholar
• 22 Coeshott C, Holmes T, Mattson A et al. Immune responses to mutated Ras – development of a yeast-based immunotherapeutic. Mol. Cancer Res. 12(Suppl. 12), A28 (2014).
  Google Scholar
• 23 Hartley ML, Bade NA, Prins PA, Ampie L, Marshall JL. Pancreatic cancer, treatment options, and GI–4000. Hum. Vaccin. Immunother. 10(11), 3347–3353 (2014).
  MedlineGoogle Scholar
• 24 Suehara N, Mizumoto K, Kusumoto M et al. Telomerase activity detected in pancreatic juice 19 months before a tumor is detected in a patient with pancreatic cancer. Am. J. Gastroenterol. 93(10), 1967–1971 (1998).
  Medline CASGoogle Scholar
• 25 Hiyama E, Kodama T, Shinbara K et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res. 57(2), 326–331 (1997).
  Medline CASGoogle Scholar
• 26 Middleton G, Silcocks P, Cox T et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, Phase 3 trial. Lancet Oncol. 15(8), 829–840 (2014).
  Medline CASGoogle Scholar
• 27 Dalgleish AG, The Image 1 Trial Investigators. Long term survival in IMAGE 1 (Immune Modulation And Gemcitabine Evaluation 1), a randomized, open-label Phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer. Presented at: 2015 ASCO Annual Meeting. IL, USA, 25–27 September 2015 (Suppl.15, Abstract 3051).
  Google Scholar
• 28 Hardacre JM, Mulcahy M, Small W et al. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a Phase 2 study. J. Gastrointest. Surg. 17(1), 94–100 (2013). •• Phase II trial in pancreatic cancer.
  MedlineGoogle Scholar
• 29 Macher BA, Galili U. The Galalpha1, 3Galbeta1, 4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim. Biophys. Acta 1780(2), 75–88 (2008).
  Medline CASGoogle Scholar
• 30 Galili U, Anaraki F, Thall A, Hill-Black C, Radic M. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 82(8), 2485–2493 (1993).
  Medline CASGoogle Scholar
• 31 Link CJ Jr, Seregina T, Atchison R, Hall A, Muldoon R, Levy JP. Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy. Anticancer Res. 18(4A), 2301–2308 (1998).
  Medline CASGoogle Scholar
• 32 Latemple DC, Abrams JT, Zhang SY, Galili U. Increased immunogenicity of tumor vaccines complexed with anti-gal: studies in knockout mice for α1,3galactosyltransferase. Cancer Res. 59(14), 3417–3423 (1999). •• Vaccination of mice with irradiated melanoma cells that express α-Gal epitopes.
  Medline CASGoogle Scholar
• 33 Rossi GR, Unfer RC, Seregina T, Link CJ. Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing alpha(1,3)galactosyl epitopes. Cancer Immunol. Immunother. 54(10), 999–1009 (2005).
  Medline CASGoogle Scholar
• 34 Hardacre JM, Mulcahy MF, Talamonti M et al. Effect of hyperacute immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer on disease-free and overall survival: preliminary analysis of Phase II data. J. Clin. Oncol. 28(Suppl. 15), Abstract 4059 (2010). •• Phase II in pancreatic cancer.
  Google Scholar
• 35 Hemstreet GP, Rossi GR, Pisarev VM et al. Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens. J. Immunother. 36(1), 57–65 (2013).
  Medline CASGoogle Scholar
• 36 Riker AI, Rossi GR, Masih P et al. Combination immunotherapy for high-risk resected and metastatic melanoma patients. Ochsner J. 14(2), 164–174 (2014).
  MedlineGoogle Scholar
• 37 Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299(9), 1019–1026 (2008).
  Medline CASGoogle Scholar
• 38 Rossi GR, Hardacre JM, Mulcahy MF et al. Effect of algenpantucel-L immunotherapy for pancreatic cancer on anti-mesothelin antibody (Ab) titers and correlation with improved overall survival. J. Clin. Oncol. 31(Suppl.), Abstract 3007 (2013).
  Google Scholar
• 39 Rossi GR, Rocha Lima CMS, Hardacre JM et al. Correlation of anti-calreticulin antibody titers with improved overall survival in a Phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer. J. Clin. Oncol. 32(Suppl. 5), Abstract 3029 (2014).
  Google Scholar
• 40 Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13(1), 54–61 (2007).
  Medline CASGoogle Scholar
• 41 De Bruyn M, Wiersma VR, Helfrich W, Eggleton P, Bremer E. The ever-expanding immunomodulatory role of calreticulin in cancer immunity. Front. Oncol. 5, 35 (2015).
  MedlineGoogle Scholar
• 42 Argani P, Iacobuzio-Donahue C, Ryu B et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 7(12), 3862–3868 (2001).
  Medline CASGoogle Scholar